Vericel Co. (NASDAQ:VCEL) Holdings Raised by Arizona State Retirement System

Arizona State Retirement System grew its position in Vericel Co. (NASDAQ:VCEL – Get Rating) by 4.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,981 shares of the biotechnology company’s stock after acquiring an additional 457 shares during the quarter. Arizona State Retirement System’s holdings in Vericel were worth $316,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in VCEL. Conestoga Capital Advisors LLC increased its holdings in shares of Vericel by 53.6% in the 4th quarter. Conestoga Capital Advisors LLC now owns 2,346,776 shares of the biotechnology company’s stock valued at $61,814,000 after acquiring an additional 818,455 shares during the last quarter. State Street Corp raised its stake in shares of Vericel by 15.6% in the 2nd quarter. State Street Corp now owns 3,400,735 shares of the biotechnology company’s stock worth $85,631,000 after buying an additional 458,219 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of Vericel by 23.8% in the 4th quarter. Fisher Asset Management LLC now owns 1,760,522 shares of the biotechnology company’s stock worth $46,372,000 after buying an additional 338,887 shares in the last quarter. Sei Investments Co. raised its stake in shares of Vericel by 1,737.4% in the 2nd quarter. Sei Investments Co. now owns 221,348 shares of the biotechnology company’s stock worth $5,574,000 after buying an additional 209,301 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of Vericel by 109.8% during the third quarter. Marshall Wace LLP now owns 249,317 shares of the biotechnology company’s stock worth $5,784,000 after purchasing an additional 130,485 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on VCEL shares. StockNews.com started coverage on Vericel in a research report on Thursday, May 18th. They set a “hold” rating on the stock. Truist Financial boosted their target price on Vericel from $31.00 to $36.00 in a research note on Thursday, May 11th. Stephens boosted their target price on Vericel from $39.00 to $42.00 in a research note on Thursday, May 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Vericel in a research note on Friday, January 27th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, Vericel currently has an average rating of “Hold” and an average target price of $37.25.

Vericel Trading Up 6.2 %

Shares of VCEL opened at $34.52 on Tuesday. Vericel Co. has a 1 year low of $17.30 and a 1 year high of $35.46. The stock has a 50 day simple moving average of $30.91 and a 200-day simple moving average of $27.90. The stock has a market cap of $1.64 billion, a PE ratio of -93.30 and a beta of 1.77.

Vericel (NASDAQ:VCEL – Get Rating) last released its quarterly earnings results on Thursday, February 23rd. The biotechnology company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.10. The business had revenue of $52.70 million for the quarter, compared to analyst estimates of $52.95 million. Vericel had a negative return on equity of 9.26% and a negative net margin of 10.11%. Vericel’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.09 EPS. On average, sell-side analysts forecast that Vericel Co. will post -0.29 EPS for the current fiscal year.

Vericel Company Profile

(Get Rating)

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee.